Clinical Trial Update: Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects [Phase 3]

View source ↗

Summary

A Phase 3 efficacy and safety study of MYOBLOC for treating adult sialorrhea has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sialorrhea

Drugs mentioned

• MYOBLOC (rimabotulinumtoxinB)

Snippet

Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC | Conditions: Sialorrhea | Phase 3 | Status: COMPLETED | Results posted: 2019-08-15